Edwards Lifesciences Reports Q3 2026 Earnings & Raises Full-Year Outlook

Financial Results & Operational Overview

Edwards Lifesciences Corporation (NYSE: EW) reported its Q3 2026 financial results via Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Financial Metrics:

• Net Sales: $1,715.5 million, up 10.5% reported (+11.2% constant currency) compared to $1,553.1 million in Q3 2025.
• Earnings Per Share (EPS): GAAP EPS of $0.53; Adjusted diluted EPS reached $0.80, up 19% year-over-year.
• Gross Profit Margin: 78.5% GAAP (78.7% adjusted) versus 77.9% in Q3 2025.
• Operating Margin: 17.4% GAAP; 30.3% adjusted.
• Liquidity & Balance Sheet: Cash and cash equivalents totaled ~$3.1 billion against total debt of ~$600 million as of September 30, 2026.

Segment Performance:

• Transcatheter Aortic Valve Replacement (TAVR): Sales of $1.24 billion, up 8.0% reported (8.8% constant currency), driven by stable global pricing and procedure adoption.
• Transcatheter Mitral and Tricuspid Therapies (TMTT): Sales of $207 million, surging 44.0% reported (45.6% constant currency), led by adoption of PASCAL and EVOQUE platforms.
• Surgical: Global sales totaled $264 million, increasing 2.5% reported (2.8% constant currency).

FY 2026 Guidance Upgrades:

• Full-Year Sales Growth: Increased to approximately 11.5% (previously 10%–11%).
• TAVR Sales Growth: Increased to 9.0%–9.5% (previously 8%–9%).
• TMTT Sales: Raised to $780–$790 million (previously $760–$780 million).
• Adjusted EPS: Raised to $2.97–$3.05 (previously $2.95–$3.05).
• Q4 2026 Outlook: Projected net sales between $1.67 billion and $1.75 billion with adjusted EPS between $0.61 and $0.69.